MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis

Experimental and Molecular Medicine

Volumn 47, Issue , 2015, Pages

  Pathak, Surajit ^a   Grillo, Alessia Rosaria ^a   Scarpa, Melania ^b   Brun, Paola ^a   D'Incà, Renata ^a   Nai, Laura ^a   Banerjee, Antara ^a   Cavallo, Donatella ^a   Barzon, Luisa ^a   Palù, Giorgio ^a   Sturniolo, Giacomo Carlo ^a   Buda, Andrea ^a   Castagliuolo, Ignazio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LUCIFERASE; MICRORNA 155; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; MICRORNA; MIRN155 MICRORNA, HUMAN; SOCS1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CELL ISOLATION; CELL POPULATION; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE CELL; LUCIFERASE ASSAY; MALE; MYOFIBROBLAST; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; UPREGULATION; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; CELLS, CULTURED; COLITIS, ULCERATIVE; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTESTINAL MUCOSA; MALE; MICRORNAS; MIDDLE AGED; MYOFIBROBLASTS; SUPPRESSOR OF CYTOKINE SIGNALING 1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84942087816     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2015.21     Document Type: Article

References (50)

1. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014;13:3-10.
2. Corridoni D, Arseneau KO, Cominelli F. Inflammatory bowel disease. Immunol Lett 2014;161:231-235.
3. Owens BM, Simmons A. Intestinal stromal cells in mucosal immunity and homeostasis. Mucosal Immunol 2013;6:225-234.
4. Naylor AJ, Filer A, Buckley CD. The role of stromal cells in the persistence of chronic inflammation. Clin Exp Immunol 2013;171:30-35.
5. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012;19:586-593.
6. Avraham R, Yarden Y. Regulation of signalling by microRNAs. Biochem Soc Trans 2012;40:26-30.
7. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15:563-568.
8. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861-874.
9. Coskun M, Bjerrum JT, Seidelin JB, Nielsen OH. MicroRNAs in inflammatory bowel disease - pathogenesis, diagnostics and therapeutics. World J Gastroenterol 2012;18:4629-4634.
10. Iborra M, Bernuzzi F, Invernizzi P, Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev 2012;11:305-314.
11. Pekow JR, Kwon JH. MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:187-193.
12. Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunol Rev 2013;253:146-157.
13. Elton TS, Selemon H, Elton SM, Parinandi NL. Regulation of the MIR155 host gene in physiological and pathological processes. Gene 2013;532:1-12.
14. Takagi T, Naito Y, Mizushima K, Hirata I, Yagi N, Tomatsuri N et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis. J Gastroenterol Hepatol 2010;25(Suppl 1):S129-S133.
15. Wu F, Zikusoka M, Trindade A, Dassopoulos T, Harris ML, Bayless TM et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008;135:1624-1635.
16. Min M, Peng L, Yang Y, Guo M, Wang W, Sun G. MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a. Inflamm Bowel Dis 2014;20:652-659.
17. Fasseu M, Treton X, Guichard C, Pedruzzi E, Cazals-Hatem D, Richard C et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS ONE 2010;5:e13160.
18. Osada T, Ohkusa T, Yokoyama T, Shibuya T, Sakamoto N, Beppu K et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm Bowel Dis 2010;16:192-197.
19. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003;17:11-17.
20. McKaig BC, Makh SS, Hawkey CJ, Podolsky DK, Mahida YR. Normal human colonic subepithelial myofibroblasts enhance epithelial migration (restitution) via TGF-p3. Am J Physiol 1999;276:1087-1093.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-AACT method. Methods 2001;25:402-408.
22. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009;58:777-789.
23. Brenmoehl J, Miller SN, Hofmann C, Vogl D, Falk W, Schölmerich J et al. Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol 2009;15:1431-1442.
24. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGFbeta isoforms by normal and inflammatory bowel disease intestina myofibroblasts. Am J Physiol Cell Physiol 2002;282:C172-C182.
25. Bajaj-Elliott M, Breese E, Poulsom R, Fairclough PD, MacDonald TT. Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts. Am J Pathol 1997;151:1469-1476.
26. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofi-broblasts in inflammatory bowel disease. Am J Pathol 2003;162:1355-1360.
27. Horino J, Fujimoto M, Terabe F, Serada S, Takahashi T, Soma Y et al. Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodiumnduced colitis in mice. Int Immunol 2008;20:753-762.
28. Chinen T, Kobayashi T, Ogata H, Takaesu G, Takaki H, Hashimoto M et al. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved. Gastroenterology 2006;130:373-388.
29. Danese S. Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2011;300:G716-G722.
30. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111-122.
31. Chen WX, Ren LH, Shi RH. Implication of miRNAs for inflammatory bowel disease treatment: Systematic review. World J Gastrointest Pathophysiol 2014;5:63-70.
32. Iborra M, Bernuzzi F, Correale C, Vetrano S, Fiorino G, Beltrán B et al. dentification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. Clin Exp Immunol 2013;173:250-258.
33. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007;179:5082-5089.
34. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33:607-619.
35. Singh UP, Murphy AE, Enos RT, Shamran HA, Singh NP, Guan H et al. miR-155 deficiency protects mice from experimental colitis by reducing Th1/Th17 responses. Immunology 2014;143:478-489.
36. Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P et al. Upregulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor a production via increased mRNA half-life in alcoholic iver disease. J Biol Chem 2011;286:1436-1444.
37. Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T et al. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis 2009;15:328-334.
38. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. Targeting of SMAD5 inks microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010;107:3111-3116.
39. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008;28:6773-6784.
40. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001;108:601-609.
41. Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ et al. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 2008;68:3152-3160.
42. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 2009;1792:497-505.
43. Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by cholinedeficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009;50:1152-1161.
44. Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS ONE 2012;7:e46082.
45. Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 2013;38:742-753.
46. Wang P, Hou J, Lin L, Wang C, Liu X, Li D et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol 2010;185:6226-6233.
47. Cardoso AL, Guedes JR, Pereira de Almeida L, Pedroso de Lima MC. miR-155 modulates microglia-mediated immune response by downregulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 2012;135:73-88.
48. Linossi EM, Babon JJ, Hilton DJ, Nicholson SE. Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev 2013;24:241-248.
49. Yoshimura A. Regulation of Cytokine Signaling by the SOCS and Spred Family Proteins. Keio J Med 2009;58:73-83.
50. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001;193:471-481.